US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer

J Clin Oncol. 2023 Jun 20;41(18):3456-3457. doi: 10.1200/JCO.23.00615. Epub 2023 Apr 27.

Authors

Melanie Royce¹, Flora Mulkey¹, Christy Osgood¹, Erik Bloomquist¹, Laleh Amiri-Kordestani¹

Affiliation

¹ Melanie Royce, MD, PhD, Flora Mulkey, MS, Christy Osgood, MD, Erik Bloomquist, PhD, and Laleh Amiri-Kordestani, MD, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

PMID: 37104738
DOI: 10.1200/JCO.23.00615

No abstract available

Publication types

Letter

MeSH terms

Adjuvants, Immunologic
Aminopyridines / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Female
Humans
Pyridines
United States
United States Food and Drug Administration

Substances

abemaciclib
Aminopyridines
Pyridines
Adjuvants, Immunologic